Literature DB >> 21177318

Diagnosis of melanoma under concomitant natalizumab therapy.

Bettina M Prinz Vavricka, Peter Baumberger, Stefan Russmann, Gerd A Kullak-Ublick.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21177318     DOI： 10.1177/1352458510389629

Source DB:  PubMed          Journal:  Mult Scler        ISSN： 1352-4585            Impact factor:   6.312


× No keyword cloud information.
  4 in total

Review 1.  Adverse events in IBD: to stop or continue immune suppressant and biologic treatment.

Authors:  Leon P McLean; Raymond K Cross
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2014-02-04       Impact factor: 3.869

Review 2.  Immunogenicity and other problems associated with the use of biopharmaceuticals.

Authors:  Michael G Tovey; Christophe Lallemand
Journal:  Ther Adv Drug Saf       Date:  2011-06

Review 3.  Melanoma complicating treatment with natalizumab for multiple sclerosis: A report from the Southern Network on Adverse Reactions (SONAR).

Authors:  Rachel A Sabol; Virginia Noxon; Oliver Sartor; Joseph R Berger; Zaina Qureshi; Dennis W Raisch; LeAnn B Norris; Paul R Yarnold; Peter Georgantopoulos; William J Hrushesky; Laura Bobolts; Paul Ray; Akida Lebby; Robert C Kane; Charles L Bennett
Journal:  Cancer Med       Date:  2017-06-20       Impact factor: 4.452

4.  Multiple Sclerosis Treatment and Melanoma Development.

Authors:  Maria Luigia Carbone; Pedro Miguel Lacal; Serena Messinese; Laura De Giglio; Carlo Pozzilli; Severino Persechino; Cinzia Mazzanti; Cristina Maria Failla; Gianluca Pagnanelli
Journal:  Int J Mol Sci       Date:  2020-04-22       Impact factor: 5.923
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.